exchange. As key cytokines involved in this process are elucidated, anticytokine therapy is The prognosis of pulmonary fibrosis is poor and current therapies inadequate. emerging as a promising prospect. Recent progress in understanding the mechanisms underlying the pathogenesis of this disease leads us to expect that Scientific basis Alveolar epithelial and/or capillary cell injury inhibitors of cytokine and polypeptide growth factor will provide novel thera-occurs early in pathogenesis (fig 1) . Circulating immune cells, including monocytes, neutropeutic agents. This paper outlines the role of cytokines in the pathogenesis of pul-phils, lymphocytes and eosinophils, are then recruited into the lung. These effector cells monary fibrosis and concludes that there are compelling reasons to explore anti-release cytokines which stimulate target cellstypically fibroblasts -to replicate and synthesise cytokine therapeutic approaches. It also proposes criteria that will enable us to increased amounts of collagen. Resident lung evaluate such agents in vivo and suggests approaches which might overcome the obstacles presented by control mechanisms which recruit a multiplicity of factors.
Pulmonary fibrosis can follow diverse insults including exposure to inhaled dusts, radiation, and certain drugs. It may complicate local or systemic pathology including pulmonary infections, sarcoidosis, and connective tissue disorders. Diffuse pulmonary fibrosis arising with no known predisposing factors is termed cryptogenic fibrosing alveolitis (idiopathic pulmonary fibrosis in the USA).
The UK prevalence of cryptogenic fibrosing alveolitis (CFA) alone is approximately five people in every 100 000. Annual mortality, around 1400, has more than doubled since 1980. Current treatment comprises corticosteroids and immunosuppressants but most 
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The last decade has generated significant R K Coker Figure 1 with pulmonary fibrosis. In the future additional cytokines may emerge that satisfy these Various cytokines have been implicated in the pathogenesis of pulmonary fibrosis, including criteria. transforming growth factor 1 (TGF-1 ), tumour necrosis factor (TNF-), plateletderived growth factor (PDGF), insulin-like Mechanisms of anticytokine therapy Anticytokine therapeutic strategies should logrowth factor 1 (IGF-1), and the interleukins IL-1 and IL-8.
1 Recently interest has also gically target one or more key events in cytokine synthesis and receptor binding (fig 1) . DNA focused on endothelin 1 (ET-1) 2 and bloodderived proteins including thrombin.
3 transcription generates an mRNA transcript whose translation results in polypeptide asOf those investigated so far, the TGF-family has the most potent stimulatory effect on sembly. Agents can inhibit protein production in several ways. Antisense oligodeoxynucleoextracellular matrix deposition. TGF-1 , secreted as a latent precursor, stimulates fibro-tides may hybridise with nuclear mRNA, activating RNases. They can also bind cytoblast procollagen gene expression and protein synthesis. It also inhibits collagen breakdown. plasmic mRNA, inhibiting ribosomal activity through steric hindrance. Alternatively, riboOur data suggest that the other mammalian TGF-isoforms, TGF-2 and TGF-3 , also zymes (RNA molecules with enzymatic activity) can prevent translation by binding and stimulate human lung fibroblast collagen synthesis and reduce degradation. 4 In experimental cleaving the mRNA transcript in the cytoplasm. TGF-1 activation requires binding to the lung fibrosis enhanced TGF-1 gene expression precedes increased collagen expression. TGF-mannose-6-phosphate receptor; agents competing for binding may therefore be antifibrotic. 1 antibodies attenuate murine bleomycin-induced lung fibrosis, and human fibrotic lung Inhibitors of growth factor-receptor binding on target cells include antibodies, soluble retissue shows increased TGF-1 gene and protein expression.
ceptors, receptor antagonists, and molecules which remove the cytokine from its site of There is also evidence to implicate tumour necrosis factor (TNF-) in the pathogenesis action. Elucidation of signal transduction pathways within the fibroblast may promote deof pulmonary fibrosis. It can promote fibroblast replication and collagen synthesis, and lung velopment of compounds which uncouple individual cytokine signalling pathways and TNF-gene expression increases in mice following bleomycin administration. Soluble block specific effects of profibrotic mediators. TNF-receptors attenuate fibrosis in murine models of lung fibrosis, 5 bronchoalveolar lavage fluid derived macrophages from patients with Therapeutic potential     CFA or asbestosis release increased amounts of TNF-, and transgenic mice overexpressing The following illustrations demonstrate the potential of anticytokine strategies as novel TNF-in alveolar epithelium develop pulmonary fibrosis. 6 treatments for pulmonary fibrosis. TGF-1 antisense reduces arterial wall proteoglycan Diminished production of potentially antifibrotic cytokines such as interferon (IFN) synthesis 8 and can eradicate established intracranial rat gliomas.
9 Mannose-6-phosphate gamma may also enhance collagen deposition in pulmonary fibrosis 7 and various physical, competes with TGF-for binding to the mannose-6-phosphate receptor, preventing TGFchemical and hormonal agents, probably interacting with cytokines, are now recognised to activation, and is under evaluation in clinical trials to reduce cutaneous wound scarring. modulate collagen production. Consequently cytokines can interact in vivo to produce Anti-TNF antibodies reduce inflammatory markers in rheumatoid arthritis 10 but imdifferent effects from those observed in vitro and target cell phenotype may modify the re-munogenicity may limit use of cytokine antibodies in pulmonary fibrosis where prolonged sponse. It may therefore be useful to establish criteria for key fibrogenic cytokines, enabling us treatment will probably be required. Soluble cytokine receptors or binding proteins may to select and develop appropriate anticytokine treatments for patients with pulmonary fibrosis. therefore provide a safer alternative. Administration of the proteoglycan decorin, a natInspired by Koch's postulates we propose that the following criteria should be satisfied before ural inhibitor of TGF-, attenuates fibrosis in an animal model of glomerulonephritis 11 as anticytokine therapy is indicated: (1) a candidate cytokine (or polypeptide growth factor) does gene therapy upregulating decorin expression. 12 Receptor antagonists effective in should stimulate fibroblast replication or procollagen production; (2) mediator gene ex-vitro are now available for TGF-1 , ET-1, and IL-1 but their value in fibrosis remains to be pression and protein production should increase in the lungs of patients with pulmonary investigated. fibrosis; and (3) inhibitors of mediator function should attenuate fibrosis in animal models of the disease.
    Multiple cytokines and polypeptide growth fac-TNF-and TGF-1 are currently the only cytokines that fulfil all three criteria. This in-tors are likely to be implicated in the pathogenesis of pulmonary fibrosis. Their functions formation provides a rational basis for developing anticytokine agents and strongly may overlap and eliminating one may be ingroup.bmj.com on April 3, 2017 -Published by http://thorax.bmj.com/ Downloaded from effective therapeutically as another takes over peutic strategies, and establishing criteria for profibrotic growth factors may guide selection its role. Possible solutions include blocking the of appropriate anticytokine therapy. The diactions of several cytokines simultaneously or versity of approaches and successful application inhibiting the actions of individual mediators at in other fields suggest there is potential for different stages of the disease process. Another developing novel anticytokine drugs to treat approach may be to identify and block intrapulmonary fibrosis. Continued research is critcellular signalling pathways common to several ical, especially into ways of targeting multiple cytokines.
growth factors, but now is the time to begin evaluating these agents in clinical trials.  
